Cooper Companies (The) (COO) Q1 2026 10-Q Quarterly Report

Filed: Mar 6, 2026Period ending Jan 31, 2026
Health Care
Ophthalmic GoodsSEC EDGAR

Cooper Companies (The) (COO) 10-Q quarterly report for Q1 2026, filed with SEC EDGAR on Mar 6, 2026 for the fiscal period ending Jan 31, 2026. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

Cooper Companies (The) Q1 2026 10-Q Analysis

Management Discussion & Analysis

  • Total revenue $1,024.1M (CooperVision $695.1M + CooperSurgical $329.0M) vs $964.7M Q1 FY2025, up ~6% YoY
  • Consolidated gross margin flat at 68%; operating margin 20.8% vs 18.9% YoY; CooperVision operating margin 30.2% vs 28.5%; CooperSurgical 8.1% vs 6.3%
+3 more insights

Risk Factors

  • No material changes from 10-K (fiscal year ended Oct 31, 2025); all prior risk factors carried forward unchanged
  • Key carried-forward risk: business faces significant risks including those not presently known or currently deemed immaterial
+1 more insights

Cooper Companies (The) Q1 2026 Quarterly Financials
XBRL

Revenue

$1.0B

+6.2% YoY

Net Income

$131M

+25.4% YoY

Gross Margin

67.9%

-55bp YoY

Operating Margin

20.8%

+191bp YoY

Net Margin

12.8%

+196bp YoY

ROE

1.6%

Total Assets

$12.4B

+0.2% QoQ

EPS (Diluted)

$0.66

+26.9% YoY

Operating Cash Flow

$261M

+36.9% YoY

Source: XBRL data from Cooper Companies (The) Q1 2026 10-Q filing on SEC EDGAR. All figures in USD.

Other Cooper Companies (The) Quarterly Reports

Get deeper insights on Cooper Companies (The)

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.